Health Care & Life Sciences » Biotechnology | Revance Therapeutics Inc.

Revance Therapeutics Inc.

Revance Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$3.81
Market Cap
$561.97 M
Shares Outstanding
44.01 M
Public Float
37.85 M

Profile

Address
7555 Gateway Boulevard
Newark California 94560
United States
Employees -
Website http://www.revance.com
Updated 07/08/2019
Revance Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders.

Financials

View All

L. Daniel Browne
President, Chief Executive Officer & Director
Mark J. Foley
Director